Reducing anti-rejection meds in ICU for kidney transplant patients
Part of Infections clinical trials.
This study tests whether quickly reducing your anti-rejection medicines during a life-threatening ICU stay can help your kidneys recover and improve your overall outcome. It is for kidney transplant recipients with septic shock or severe breathing failure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You received a kidney transplant more than 3 months ago.
- You are now in the ICU because of a severe infection causing low blood pressure (septic shock) and/or a serious lung infection causing breathing trouble.
- You take at least two anti-rejection medications (such as steroids, tacrolimus, mycophenolate, or similar).
- You are not on chronic dialysis, and your kidney function is not severely reduced (eGFR above 20).
- You are not taking belatacept (Nulojix) for anti-rejection therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether older kidney transplant recipients can safely reduce their immunosuppression medications using a special monitoring tool called Trugraf. If you are over 55, have had a stable transplant, and want to possibly lower your medications, this study may be for you.
This study tests a new approach to managing anti-rejection medicines after a heart transplant. It uses special blood tests to see if your immune system is calm, so doctors can safely reduce the medicines and lower side effects.
This study tests whether continuing certain anti-rejection medicines while on dialysis can help lower the risk of your immune system becoming too sensitive to a future kidney transplant. It might help you stay eligible for another transplant later.
This trial studies a quick set of tests to figure out whether a person with severe infection (sepsis) will respond to corticosteroids like hydrocortisone. The goal is to guide treatment sooner and avoid ineffective care.
This study tests whether giving a special mix of donor immune cells along with immune-suppressing medicines right after a kidney transplant can help the body accept the new kidney without long-term anti-rejection drugs. It aims to reduce the need for daily transplant medications.
This trial tests a special device that filters parts of the blood to calm inflammation in people with severe acute kidney injury in the ICU. It may help improve recovery and reduce complications by “deactivating” certain immune cells.
Hear when a new Sepsis and Septic Shock trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.